Drugmaker Stada Arzneimittel AG said Thursday it struck a deal to sell its stake in an American subsidiary for $40 million and plans to exit the U.S. market completely. The Bad Vilbel-based company said it would sell its stake in the Cranbury, New Jersey-based Stada Inc. to Dava Pharmaceuticals Inc.
MSN
Money
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Complaint Handling, Process Controls Lacking at Battery Maker Alpha Source
Complaint records lacked adequate documentation of the root cause or corrective actions taken.
FDA Approves Treatment for Thrombocytopenia
Both dosage levels of Doptelet led to a higher proportion of patients with increased platelet counts.
FDAnews Drug Daily Bulletin
STADA SELLS U.S. UNIT TO DAVA FOR $40M
July 14, 2006